EDSA
Edesa Biotech, Inc. · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website edesabiotech.com
- Employees(FY) 16
- ISIN CA27966L3065
Performance
+0.8%
1W
+4.71%
1M
-15.27%
3M
+59.65%
6M
-0.44%
YTD
-30.85%
1Y
Profile
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.
Technical Analysis of EDSA 2024-05-10
Overview:
In analyzing the technical indicators for EDSA over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement. By examining these key factors, we aim to offer valuable insights and predictions for the upcoming days.
Trend Analysis:
...Recent News & Updates
- 2023-04-03 20:45
- 2023-03-23 04:30
- 2023-03-16 04:10
- 2023-03-14 20:10
- 2023-02-14 16:11
EDSA: Positive News Flow to Start 2023(Yahoo Finance)
- 2023-02-11 20:00
- 2023-02-09 20:00
Edesa Biotech Reports Fiscal 1st Quarter 2023 Results(Yahoo Finance)
- 2023-01-31 19:15
- 2023-01-17 16:50
- 2023-01-16 23:30
- 2023-01-16 19:30
- 2022-12-21 17:47
EDSA: Phase 2b Data for EB01 Anticipated in January 2023(Yahoo Finance)
- 2022-12-19 19:30
FDA Grants Fast Track to Edesa Biotech's ARDS Drug Candidate(Yahoo Finance)
- 2022-12-15 20:00
Edesa Biotech Reports Fiscal Year 2022 Results(Yahoo Finance)
- 2022-12-01 19:00
- 2022-11-02 21:00
- 2022-10-02 23:10
- 2022-09-29 20:00
- 2022-09-08 04:30
- 2022-09-06 20:00
Edesa Biotech Reports Phase 2b Study Reaches Full Enrollment(Yahoo Finance)
- 2022-08-23 19:15
- 2022-08-12 04:30
Edesa Biotech Reports Fiscal 3rd Quarter 2022 Results(Yahoo Finance)
- 2022-08-02 20:15
- 2022-07-15 20:11
Edesa Biotech, Inc. (NASDAQ:EDSA): Are Analysts Optimistic?(Yahoo Finance)
- 2022-07-10 20:30
Edesa Biotech to Present at ARDS Drug Development Summit(Yahoo Finance)
- 2022-05-24 01:04
- 2022-05-23 19:55
- 2022-05-19 04:30
- 2022-05-18 22:12
- 2022-05-16 20:43